Auricular VNS Following Intracerebral Hemorrhage

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Jan 22, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a treatment called auricular vagal nerve stimulation (VNS) for patients who have experienced a type of brain bleed known as intracerebral hemorrhage (ICH). The goal is to see if this non-invasive treatment can lower inflammation in the body and improve recovery outcomes for patients after their bleed. The study is currently looking for adult participants aged 65 to 74 who have been admitted to Barnes Jewish Hospital with a spontaneous brain bleed.

To be eligible for the trial, participants must meet certain criteria. They should be adults who have had a specific type of ICH and can be enrolled within 48 hours of their bleed. However, people who are under 18, have certain serious conditions, or are in immediate danger may not qualify. If you decide to participate, you can expect to receive the auricular VNS treatment and be monitored for its effects on your recovery. This trial aims to find new ways to help patients heal and improve their quality of life after a brain bleed.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients who present with a spontaneous supratentorial intracerebral hemorrhage (ICH) to Barnes Jewish Hospital
• Exclusion Criteria:
• • Patients \< 18 years old
• • Patients with a presumed traumatic etiology for their ICH, infratentorial location, ICH volume \> 60 ml or \< 10 ml, at risk of imminent death (e.g. Glasgow Coma Scale, GCS of 3 or one or more pupils unreactive), surgical intervention imminently planned (not including ventriculostomy)
• • Patients undergoing active cancer therapy
• • Patients with sustained bradycardia on arrival with a heart rate \< 50 beats per minute.
• • Patients who cannot be enrolled within 48 hours of the initial bleed.